To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Dysmenorrhea Clinical Trial

Official title:

A Multinational, Double-blind, Randomized, Placebo-controlled, Parallel-group Clinical Study to Investigate the Efficacy and Safety of the Oral Hormonal Contraceptive BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) Over 16 Weeks for the Treatment of Women With Dysmenorrhea

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02617537
• Other study ID #: 16419
• Secondary ID: 2015-003924-29
• Status: Withdrawn
• Phase: Phase 3
• First received: November 23, 2015
• Last updated: February 15, 2016
• Start date: January 2016
• Est. completion date: October 2017

Study information

• Verified date: February 2016
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical DevicesRussia: Federal Service on Surveillance in Health Care
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to investigate the safety and efficacy of (0.02 mg EE as betadex clathrate [β-CDC]) / 3 mg drospirenone (DRSP) for dysmenorrhea. In order to appropriately evaluate the efficacy of EE(β-CDC)/DRSP the study was set up as a placebo-controlled comparative study

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients suffering from dysmenorrhea for at least the previous 3 months prior to Visit 1 with a minimum visual analogue scale (VAS) score of 30 mm with regard to pain during the menstrual period of the screening period

• Good general health (except for findings related to dysmenorrhea) as proven by medical history

• Patients aged 18 years or older at the time of obtaining informed consent; smokers must not be older than 35 years at the time point of informed consent

• Normal or clinically insignificant cervical smear not requiring further follow up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the previous six months). Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASCUS) can be used as an adjunctive test. Subjects with ASCUS can be included if they are negative for high-risk HPV strains (HPV 16, HPV18).

• Women of childbearing potential must agree that adequate contraception will be used when they are sexually active. This applies from signing of the informed consent form until 2 weeks after the last study drug administration.

Exclusion Criteria:

• Pregnancy (confirmed or suspected) or lactation (less than three months since delivery, abortion, or lactation before start of treatment)

• Patients who wish to become pregnant during the course of the study

• Body Mass Index (BMI) > 32 kg/m2

• Hypersensitivity to any ingredient of the study drug

• Laboratory values outside inclusion range before randomization

• Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication

• Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results

• Any disease or condition that may worsen under hormonal treatment according to the assessment and opinion of the investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dysmenorrhea

Intervention

Drug:
• EE20/DRSP(YAZ,BAY86-5300)
0.02 mg EE (ß-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
• Placebo
Matching placebo tablets for 28 days per 28-day intake cycle

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in visual analogue scale (VAS) score for pain due to dysmenorrhea from baseline to Visit 6	The patient marks the individual pain impression on a visual analogue scale in the range 0 (no pain) to 100mm (worst pain ever experienced)	Baseline to week 17	No
Secondary	Number of participants with adverse events as measure of safety and tolerability		Up to 16 weeks	Yes
Secondary	Number of days with dysmenorrhea	The occurrence of dysmenorrhea will be recorded in the patient diary	Up to 16 weeks	No
Secondary	Change in dysmenorrhea score	It is the sum of two four-stage sub-scales which assess the extent to which dysmenorrhea interferes with daily life & the extent to which pain medication is used.	Baseline to week 16	No
Secondary	Changes from baseline to each menstrual period of total number of taken supportive analgesic medication	Standard Analgesic tablets are provided to participants	Baseline to week 16	No
Secondary	Changes from baseline to each menstrual period of days without supportive analgesic medication.		Baseline to week 16	No
Secondary	Clinical Global Impression(CGI)	The CGI is the measure of global improvement index from the opinion of the investigator and subject to document changes in the health status during treatment	At week 16	No
Secondary	Self administered SF-36 questionnaire	The 36-items Short Form Health Survey (SF-36) (version 2.0) is a set of generic, coherent,and easily administered quality-of-life measures.	At baseline and week 17	No
Secondary	Changes from baseline to each menstrual period of severity of lumbago	The patient classifies the severity on a mild, moderate, severe scale	Up to 16 weeks	No
Secondary	Changes from baseline to each menstrual period of severity of headache	The patient classifies the severity on a mild, moderate, severe scale	Up to 16 weeks	No
Secondary	Changes from baseline to each menstrual period of severity of nausea/vomiting	The patient classifies the severity on a mild, moderate, severe scale	Up to 16 weeks	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.